Braeburn Announces Completion Of $110 Million Financing

Braeburn Pharmaceuticals, Inc. (Braeburn) recently announced its completion of $110 million in financing. The financing efforts—led by Wellington Capital Management—included numerous investors, with the funds going towards advancing U.S. Food and Drug Administration (FDA) approval and commercialization of CAM2038.

CAM2038 is an investigational buprenorphine weekly and monthly depot subcutaneous injection for the treatment of opioid use disorder, as a part of a comprehensive treatment plan to include counseling and psychosocial support. Additionally, Braeburn seeks to use proceeds to further expand treatment options for people battling opioid addiction, of whom only a fraction are receiving the treatment they . . .